Trial Profile

An open label extension study of Varoglutamstat to patients who have been treated under VIVIAD or VIVA-MIND protocols

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 29 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Varoglutamstat (Primary)
Indications Alzheimer's disease; Cognition disorders; Mild cognitive impairment
Focus Therapeutic Use
Acronyms VIVALONG

24 Apr 2024 According to a Vivoryon Therapeutics media release, In line with the Companys cost reduction measures and given the developments of VIVIAD and VIVA-MIND, Vivoryon has decided to stop VIVALONG OLE study preparation activities
26 Oct 2023 According to a Vivoryon Therapeutics media release, the company has commenced preparations for an open-label extension (OLE) study I July 2023, to provide a long-term treatment option to patients after completion of treatment under the VIVIAD or VIVA-MIND protocol.
18 Jul 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com